Nanocarrier medicine has entered a paradox. The chemistry to make targeted, multi-functional carriers is now routine, and the clinical need - most sharply in cancers such as colorectal carcinoma - is unambiguous, yet fewer than one in ten preclinical candidates reaches patients, and the fraction of an injected dose that reaches a solid tumour remains small. The bottleneck is not synthetic capacity but interpretation: nanocarrier physicochemistry, in vitro biological behaviour and patient-level clinical variability are measured in disconnected assays, and no single framework couples them into an actionable prediction for a specific patient. We propose that this coupling is best cast as a three-layer virtual twin. Layer 1 is the nanocarrier physicochemical feature space (size, shape, coating, corona, payload). Layer 3 is the patient biological profile drawn from routine clinical-laboratory data (molecular status, tumour markers, systemic-inflammation indices). Between them sits Layer 2, an intermediate integrating layer of multi-modal AI/ML biosensing. We formalise the concept, show how each layer is populated with concrete quantitative examples (drawn from a validated microfluidic biosensing platform and from published colorectal-cancer laboratory data), and argue that a personalised, safety-gated decision index emerges naturally from the fusion. We conclude with a maturation trajectory that turns this concept into a practical instrument for personalised nanomedicine.